Treatment of Ovarian Cancer Through Anti-Cancer Strategy

Abstract

Mitochondrial biogenesis is essential for cell's replication and survival and is required in chemo resistance. The chemo resistance is the pre-eminent deterrent in the treatment of patients with ovarian disease. A few studies demonstrated that adjustment of MtBIO can prompt disease cell passing. In this manner focusing on MtBIO in ovarian disease could be a promising approach potentially through defeating the chemo resistance.

Keywords

Ovarian cancer, Targeted therapy, Replication

Introduction

Ovarian tumor is the most deadly gynecologic threat overall normally in the post-menopausal ladies and fifth driving reason for death in the United States [1-3]. Around 80% of ladies are analyzed at the propelled phase of ailment and have poor anticipation. The 5-year general survival rate is 45% or beneath [4-6]. In spite of the main complete reaction after the bleeding edge platinum-based chemotherapeutic medications [7,8], around 25% patients experience the ill effects of backslide inside 6 months who are thought, by definition, to have a chemo resistance [9-12]. Mix of platinum and different medications may enhance the survival rate [13], yet is not out of the risk of added substance danger [14].

A few hereditary adjustments have been seen in ovarian disease, including deactivation changes in tumor silencer qualities, for example, p53, BRCA1 and BRCA2, and actuation transformation and/or intensification of proto-oncogenes, similar to c-MYC, KRAS and AKT [15]. Late genomic investigation of The Cancer Genome Atlas reported changes in p53 quality in 96% of 316 instances of high-review ovarian serous carcinoma (HGOSC) [16]. Other imperative hereditary changes influence phosphatidyinositol-3-kinase (PI3K)-AKT-mammalian focus of rapamycin (mTOR) course. The mTOR assumes a focal part in vitality digestion system, cell development/division through macromolecular amalgamation and is observed to be initiated in ovarian tumor [6], which demonstrates a cozy relationship between hereditary change and vitality digestion system. It was watched that hexokinase (HK) II, the rate constraining beginning compound in glycolysis, is overexpressed in ovarian growth [12]. The hereditary changes and ensuing metabolic redesigning have been observed to be connected with the chemo resistance [17], for example, relationship of rictor (mTORC2 part) with imperviousness to cisplatin [2]. Cisplatin-affected caspase enactment bringing on PTEN cleavage has additionally been accounted for as a potential system of chemo resistance in ovarian growth [18].

 Ovarian Cancer: Metabolic Remodeling and It’s Chemoresistance

Vital Clinicopathologic and Hereditary Adjustment

As indicated by the Gynecologic Oncology Group and European-Canadian specialists, platinum-and taxane-based chemotherapy after surgery has been considered as the powerful treatment regimen against ovarian disease with 60% to 80% in general reaction rate. In any case, among the backslid patients reaction rate diminished to 15% to 35% to the same treatment regimen. Diverse hereditary modifications have been recognized in ovarian disease. HGOSC all around demonstrated p53 quality change, trailed by genomic precariousness, DNA duplicate number anomalies and so forth [19,20]. The PI3K/AKT/mTOR pathway is a standout amongst the most imperative hereditary adjustment in ovarian disease, generally actuated because of the changes in PI3KCA quality. Modification of PI3KCA likewise prompts mTOR phosphorylation and improve tumor survival. Enactment of PI3K pathway causes overexpression of BAD, PAK1, GSK3B and so on. Different adjustments are seen in RB, RAS and NOTCH pathways. RB1 itself is observed to be erased or changed. CDK inhibitor (p16) inactivation permits the enhancement of Cyclin E1 which further represses RB1 by means of Cyclin D1 and Cyclin D2 qualities. Cancellation or change of NF1 enact KRAS-BRAF connected survival pathway. Indent quality gets actuated either by means of JAG1-2 or MAML1-3. In addition, deregulated JAG1-NOTCH1 flagging can initiate gathering of oncogenes, including MYC families conceivably connected with ovarian malignancy movement. It was watched that FOXM1 translation component system is enacted in 84% of cases. Erasure transformations in BRCA1 and BRCA2 are additionally normal in HGOSC. In poor quality ovarian serous carcinoma, most predominant transformations are recognized in PI3KCA, BRAF and KRAS qualities. ARID1A is much of the time changed in clear-cell and poor quality endometrioid ovarian growth. 33% of clear cell tumors contain PIK3CA quality transformations. Mucinous sort is accounted for to contain about 100% KRAS transformation and a high recurrence of HER2 enhancement. Along these lines hereditary changes are nearly connected with clinicopathologic elements of ovarian malignancy patients [21-30].

Metabolic Changes in Connection to Hereditary Changes

Hereditary adjustments a large number of the time causes metabolic changes inside a cell. Heredita pathways other than its traditional tumor suppressive capacities, for example, glycolysis, OXPHOS, and amino corrosive digestion system. It likewise assumes a critical part in lipid and lipoprotein digestion system. Accordingly it can be expected that mutant p53 could assume a more noteworthy part in metabolic reinventing. In HGOSC mutant p53 can improve lipid anabolism through the association with sterol administrative component restricting proteins and guanidinoacetate N-methyltransferase, prompting unsaturated fats and cholesterol biosynthesis and the restraint of unsaturated fat oxidation (FAO). PI3K flagging is one of the significant controllers of glucose digestion system through the declaration of glucose transporter GLUT1 by AKT. AKT upgrades glycolytic flux mostly by the upkeep of HK, bolsters malignancy cells for improved multiplication. Glucose digestion system additionally can be advanced by RAS through improving glucose uptake. AKT assumes a critical part in glucose transport and controls glucose stockpiling by GSK3 restraint. AKT additionally included in gluconeogenesis and FAO through FOXOs. As of late its part in controlling lipid digestion system has been demonstrated by means of tweak of cAMP [31-40].

Chemoresistance Based on Metabolic Remodeling

Metabolic rebuilding of tumor cells makes the cells impervious to certain chemotherapeutics. One of the major chemoresistant components received by the disease cells is the evasion of apoptosis. A key occasion of early apoptosis is the permeabilization of external mitochondrial film (OMM) which causes the arrival of cytochrome-c. Permiabilization can be accomplished by voltage-subordinate anion channel (VDAC) and mitochondrial apoptosis-actuated channel (MAC) dwells in the OMM, and mitochondrial penetrability move pore (MPTP) which comprises of VDAC at OMM and adenine nucleotide transporter (ANT) at internal mitochondrial layer (IMM) [41-44]. These pore frameworks depend on genius apoptotic protein Bax, Bad to open in this way under the control of hostile to apoptotic BCL-2 family proteins, for example, BCL-XL. OMM permeabilization is further accomplished by the connection of VDAC and ANT proteins. Harmful ovarian disease cells oftentimes overexpress HK II, which is found to forestall tumor apoptosis through official with VDAC or through hindrance of VDAC-ANT connection. AKT, a metabolic controller of glycolysis, is overexpressed in ovarian tumor and proof recommends that it improve OMM solidness, consequently repressing apoptotic cell passing. AKT is found to inactivate caspase-9 and incite XIAP expression. Enacted AKT squares ubiquitination of FLIP in p53 subordinate way restrains Bax oligomerization and inactivates Bad through phosphorylation. Further, AKT initiation encourages BCL-XL and HK II translocation to mitochondrial pore complex particularly to VDAC. Notwithstanding BCL-XL, MCL-1 is upregulated much of the time in ovarian tumor and connected with chemoresistance. CD95 expression in ovarian growth is accounted for to be connected to the chemoresistance. HIF-1α, another essential quality connected with ovarian growth, upregulate IPA-2, MDM2 and VEGF and hinders TRAIL prompted Bax translocation on mitochondria [45-50].

Anti-Cancer Strategy

There are proofs that ovarian malignancy cells keep up in place OXPHOS capable on mitochondria with useful TCA cycle for their survival as far as film potential, ATP biosynthesis and oxygen utilization despite the fact that their mitochondria may contain transformed DNA and gather diverse unsafe items, for example, ROS. Disease cells in ovarian malignancy can ensure themselves through the support of all around appropriated mitochondrial biomass and, MtBIO makes growth cells impervious to chemotherapeutics and is considered as a developing component of chemoresistance. Mitochondria are required for the survival of living beings living under the vigorous environment [51-53].

TFAM

TFAM (otherwise called mtTFA) is an atomic encoded 25 kDa protein individual from the high portability bunch (HMG) box protein family and a key controller of MtBIO. Upon import to mitochondria it plays out numerous administrative capacities including mtDNA interpretation, support of mtDNA circling, covering and bundling (mitochondrial nucleoids). It contains aspects for restricting atomic respiratory variable (NRF) 1 and NRF2 which follow up on the promoter of D-circle locale prompting expanded mtDNA duplicate number. Noteworthy overexpression of TFAM was seen in human serous ovarian growth in relationship with poor 5-years survival. TFAM likewise works through official with its downstream target BCL-XL. The study has proposed TFAM as a respectable remedial focus for ovarian tumor. Next to ovarian malignancy, TFAM upregulation is additionally seen in bosom, colorectal, bladder, endometrial and arsenic impelled skin growth with resulting increment in MtBIO and cell expansion. Numerous study show comparative results both in test and clinical settings [54-60]. Such discoveries recommend TFAM as a standout amongst the most vital remedial focuses in chemoresistant ovarian growth.

PHB-1

Prohibitin has a place with a rationed protein family, which contain a prohibitin (PHB) area all the more particularly, stomatin/prohibitin/flotillin/HflK/C (SPFH) space saw in a different gathering of life forms from prokaryote to human. It is communicated universally in various compartments of the cell, for example, mitochondria, core and cytosol, and transported among them. PHB-1 has been observed to be required in chemoresistance in ovarian tumor cells and principally connected with mitochondria. It is overexpressed in papillary serous ovarian carcinoma and in addition endometrioid ovarian adenocarcinoma. This profoundly rationed protein can direct cell cycle at G0/G1 stage furthermore present cell survival. In mitochondria, PHB-1 manages gathering of respiratory complex 1 and subunits of cytochrome c oxidase; also, it influences mitophagy. Inactivation of PHB-1 capacity can bring about imperfections in mitochondria respiratory chain and morphological twisting of mitochondria. Focusing on PHB-1 in ovarian malignancy may prompt a promising result in ovarian disease treatment [61-70].

MCL-1

MCL-1 is a hostile to apoptotic BCL-2 family protein and its consistent interpretation is required for the restraint of apoptosis. Chemoresistant A2780 cells were found to express around 8 fold more elevated amount of MCL-1 than parental and its downregulation by another individual from BCL-2 family protein called PUMA (p53 upregulated modulator of apoptosis) was found to chemosensitize ovarian growth cells (A2780 and SKOV-3). Concealment of MCL-1 by an intense hostile to growth specialist RKS262 was found to upgrade cell passing in ovarian malignancy cell line, OVCAR-3. It is clear from late looks into that BCL-2 family assumes an imperative part in the control of splitting combination elements of mitochondria through ionic homeostasis and autophagy [71-80]. As an individual from BCL-2 family, MCL-1 assumes a honorable part in mitochondrial progression. To perform such assignment it should be truncated at amino terminal and to be transported into the mitochondrial grid. Once in framework it manages mitochondrial combination maybe in conjunction with optic decay 1 (OPA-1). It was watched that hindrance of MCL-1 causes lessening of OPA-1 action, which prompts the weakness of mitochondrial combination, thusly mitochondrial fracture increments. Such discontinuity was quick and free of dynamin-related protein-1 (DRP-1) without critical ATP exhaustion and adjustment of mitochondrial buildings (I-V) [81-90]. In mitochondrial grid, MCL-1 can be corrupted by GSK3β. MCL-1 can serve as another objective to confine MtBIO for beating the chemoresistance in ovarian malignancy.

BNIP3

BNIP3 is another individual from the Bcl-2 family and observed to be overexpressed in the hypoxic zone of numerous tumors, including bosom disease, glioma and ovarian growth. It is communicated on OMM and included in mitochondrial parting and mitophagy, accordingly diminishing aggregate mitochondrial biomass. The other capacity of BNIP3 is to affect cell passing through mitochondrial brokenness because of HIF-1 [91-100]. Be that as it may, when its transmembrane space is lost or truncated, it neglected to play out the above undertaking. It has been watched that in ovarian malignancy cells such sort of truncated BNIP3 with the loss of transmembrane area is overexpressed. Contribution of in place BNIP3 in the direction of mitochondrial biomass is basic for disease cells demise, in this way BNIP3 can be a reasonable atomic focus for ovarian malignancy.

References

1. Yoboue ED, et al. The role of mitochondrial biogenesis and ROS in the control of energy supply in proliferating cells. BiochimBiophysActa. 2014;1837:1093-1098.
2. Itoh K, et al. Mitochondrial dynamics in neurodegeneration. Trends Cell Biol. 2013;23:64-71.
3. Johri A and Beal MF. Mitochondrial dysfunction in neurodegenerative diseases. J PharmacolExpTher. 2012;342:619-630.
4. De Moura MB, et al. Mitochondrial dysfunction in neurodegenerative diseases and cancer. Environ Mol Mutagen. 2010;51:391-405.
5. Diaz F and Moraes CT. Mitochondrial biogenesis and turnover. Cell Calcium. 2008;44:24-35.
6. Schusdziarra C, et al. Methylation-controlled J-protein MCJ acts in the import of proteins into human mitochondria. Hum Mol Genet. 2013;22:1348-1357.
7. Farrand L, et al. Piceatannol enhances cisplatin sensitivity in ovarian cancer via modulation of p53, X-linked inhibitor of apoptosis protein (XIAP), and mitochondrial fission. J BiolChem. 2013;288:23740-23750.
8. Sinha D and D'Silva P. Chaperoning mitochondrial permeability transition: regulation of transition pore complex by a J-protein, DnaJC15. Cell Death Dis. 2014;5:e1101.
9. Gregory-Bass RC, et al. Prohibitin silencing reverses stabilization of mitochondrial integrity and chemoresistance in ovarian cancer cells by increasing their sensitivity to apoptosis. Int J Cancer. 2008;22:1923-1930.
10. Ahn CS, et al. Prohibitin is involved in mitochondrial biogenesis in plants. Plant J. 2006;46:658-667.
11. Sripathi SR, et al. Mitochondrial-nuclear communication by prohibitin shuttling under oxidative stress. Biochemistry. 2011;50:8342-8351.
12. Varadarajan S, et al. Sabutoclax (BI97C1) and BI112D, putative inhibitors of MCL-, induce mitochondrial fragmentation either upstream of or independent of apoptosis. Neoplasia. 2013;15:568-578.
13. Jebahi A, et al. PI3K/mTOR dual inhibitor NVP-BEZ235 decreases Mcl-1 expression and sensitizes ovarian carcinoma cells to Bcl-xL-targeting strategies, provided that Bim expression is induced. Cancer Lett. 2014;348:38-49.
14. Kim HS, et al. In vitro extreme drug resistance assay to taxanes or platinum compounds for the prediction of clinical outcomes in epithelial ovarian cancer: a prospective cohort study. J Cancer Res ClinOncol. 2009;135:1513-1520.
15. Lee HJ, et al. Feasibility of Oxaliplatin, Leucovorin, and 5-Fluorouracil (FOLFOX-4) chemotherapy in heavily pretreated patients with recurrent epithelial ovarian cancer. Cancer Res Treat. 2013;45:40-47.
16. Cancer Genome Atlas Research Network. Integrated genomic analyses of ovarian carcinoma. Nature. 2011;474:609-615.
17. Weberpals JI, et al. Targeting genetic and epigenetic alterations in the treatment of serous ovarian cancer. Cancer Genet. 2011;204:525-535.
18. Liu MX, et al. Epigenetic silencing of microRNA-199b-5p is associated with acquired chemoresistance via activation of JAG1-Notch1 signaling in ovarian cancer. Oncotarget. 2014;5:944-958.
19. Munksgaard PS, et al. The association between endometriosis and ovarian cancer: a review of histological, genetic and molecular alterations. GynecolOncol. 2014;124:164-169.
20. Bensaad K, et al. TIGAR, a p53-inducible regulator of glycolysis and apoptosis. Cell 2006;126:107-120.
21. Suzuki S, et al. (2010) Phosphate-activated glutaminase (GLS2), a p53-inducible regulator of glutamine metabolism and reactive oxygen species. ProcNatlAcadSci. 2010;107:7461-7466.
22. Matoba S, et al. p53 regulates mitochondrial respiration. Science. 2006;312:1650-1653.
23. Kawauchi K, et al. p53 regulates glucose metabolism through an IKK-NF-kappaB pathway and inhibits cell transformation. Nat Cell Biol. 2008;10:611-618.
24. Hu W, et al. Glutaminase 2, a novel p53 target gene regulating energy metabolism and antioxidant function. ProcNatlAcadSci. 2010;107:7455-7460.
25. Goldstein I, et al. p53, a novel regulator of lipid metabolism pathways. J Hepatol. 2012;56:656-662.
26. Hu J, et al. Does TP53 mutation promote ovarian cancer metastasis to omentum by regulating lipid metabolism? Med Hypotheses. 2013;81:515-520.
27. Barthel A, et al. Regulation of GLUT1 gene transcription by the serine/threonine kinase Akt1. J BiolChem. 1999;274:20281-20286.
28. Vander Heiden MG, et al. Growth factors can influence cell growth and survival through effects on glucose metabolism. Mol Cell Biol. 2001;21:5899-5912.
29. Lunt SY, et al. Aerobic glycolysis: meeting the metabolic requirements of cell proliferation. Annu Rev Cell DevBiol. 2011;27:441-464.
30. Yun J, et al. Glucose deprivation contributes to the development of KRAS pathway mutations in tumor cells. Science. 2009;325:1555-1559.
31. Cecconi S, et al. The role of Aktsignalling in the mammalian ovary. Int J DevBiol. 2012;56:809-817.
32. Hers I, et al. Aktsignalling in health and disease. Cell Signal. 2011;23:1515-1527.
33. Pennington K, et al. Too much of a good thing: suicide prevention promotes chemoresistance in ovarian carcinoma. Curr Cancer Drug Targets. 2010;10:575-583.
34. Wang Y, et al. Up-regulation of mitochondrial antioxidation signals in ovarian cancer cells with aggressive biologic behavior. J Zhejiang UnivSci. 2011;B12:346-356.
35. Kunej T, et al. Functional UQCRC1 polymorphisms affect promoter activity and body lipid accumulation. Obesity (Silver Spring). 2007;15:2896-2901.
36. Sotgia F, et al. Cancer metabolism: new validated targets for drug discovery. Oncotarget. 2013;4:1309-1316.
37. Lim HY, et al. Respiratory competent mitochondria in human ovarian and peritoneal cancer. Mitochondrion. 2011;11:437-443.
38. Permuth-Wey J, et al. Inherited variants in mitochondrial biogenesis genes may influence epithelial ovarian cancer risk. Cancer Epidemiol Biomarkers Prev. 2011;20:1131-1145.
39. Liu VW, et al. High incidence of somatic mitochondrial DNA mutations in human ovarian carcinomas. Cancer Res. 2011;61:5998-6001.
40. Kurita T, et al. Mitochondrial transcription factor A regulates BCL2L1 gene expression and is a prognostic factor in serous ovarian cancer. Cancer Sci. 2012;103:239-444.
41. Boland ML, et al. Mitochondrial dysfunction in cancer. Front Oncol. 2013;3:292.
42. Sena LA, et al. Physiological roles of mitochondrial reactive oxygen species. Mol Cell. 2013;48:158-167.
43. Bensinger SJ, et al. New aspects of the Warburg effect in cancer cell biology. Semin Cell DevBiol. 2012;23:352-361.
44. Pavlides S, et al. The reverse Warburg effect: aerobic glycolysis in cancer associated fibroblasts and the tumor stroma. Cell Cycle. 2009;8:3984-4001.
45. Koppenol WH, et al. Otto Warburg's contributions to current concepts of cancer metabolism. Nat Rev Cancer. 2011;11:325-337.
46. Jang M, et al. Cancer cell metabolism: implications for therapeutic targets. ExpMol Med. 2013;45:e45.
47. Martinez-Outschoorn UE, et al. Stromal-epithelial metabolic coupling in cancer: integrating autophagy and metabolism in the tumor microenvironment. Int J Biochem Cell Biol. 2013;43:1045-1051.
48. Martinez-Outschoorn UE, et al. Power surge: supporting cells "fuel" cancer cell mitochondria. Cell Metab. 2012;15: 4-5.
49. Isonishi S, et al. Mitochondria in platinum resistant cells. Hum Cell. 2001;14:203-210.
50. Hallberg BM, et al. TFAM forces mtDNA to make a U-turn. Nat StructMolBiol. 2011;18:1179-1181.
51. Mabuchi S, et al. TargetingmTORcomplexes in ovarian cancer. J Cancer SciTher. 2011;6:211-216.
52. Farghaly SA. Novel targeted therapies for patients with ovarian cancer. J Cancer SciTher. 2014;6:e133.
53. Lee G, et al. Two distinct humanized monoclonal antibodies for immunotherapy of ovarian cancer. J Cancer SciTher. 2014;6:110-116.
54. Nakamura T, et al. Paradoxical augmentation of tumor angiogenesis combined with down-regulation of IP-10 after adenovirus-mediated transfer of vasohibin-1 gene in cancer cells. J Cancer SciTher. 2014;6:289-297.
55. Ricci F, et al. Ovarian cancer recurrence: role of ovarian stem cells and epithelial-to-mesenchymal transition. J Cancer SciTher. 2014;6:298-305.
56. Toss A and Cortesi L. Molecular mechanisms of PARP inhibitors in BRCA-related ovarian cancer. J Cancer SciTher. 2013;5:409-416.
57. Uddin MH, et al. Anticancer strategy targeting mitochondrial biogenesis in ovarian cancer. J Cancer SciTher. 2014;6:422-428.
58. Elit L and Hirte H. Novel targeted therapies in ovarian cancer. J Cancer SciTher. 2014;6:350-362.
59. Ahmed AH, et al. EDL-360: A potential novel antiglioma agent. J Cancer SciTher. 2014;6:370-377.
60. Vidhyalakshmi R and Vallinachiyar C. Apoptosis of human breast cancer cells (MCF-7) induced by polysacccharides produced by bacteria. J Cancer SciTher. 2013;5:031-034.
61. Imtiyaz Ahmad AB, et al. Inactivation of RIZ1 gene by promoter hypermethylation is associated with disease progression and resistance to imatinib in indian chronic myelogenous leukemia patients, first study from India. J Cancer SciTher. 2013;5:045-051.
62. Oliveira MS, et al. Doxorubicin cardiotoxicity and cardiac function improvement after stem cell therapy diagnosed by strain echocardiography. J Cancer SciTher. 2013;5:052-057.
63. ArantesFaria JAQ, et al. SET domain-containing Protein 4 (SETD4) is a newly identified cytosolic and nuclear lysine methyltransferaseinvolved in breast cancer cell proliferation. J Cancer SciTher. 2013;5:058-065.
64. Rao VD. MicroRNA: A new promising biomarker. J Cancer SciTher. 2013;5:066-068.
65. Mishra SK, et al. Molecular basis of aging and breast cancer. J Cancer SciTher. 2013;5:069-074.
66. Omoomi FD, et al. Molecular chlorambucil-methionine conjugate: novel anticancer agent against breast MCF-7 cell model. J Cancer SciTher. 2013;5:075-084.
67. Maleek MI. Omega-3 fatty acids decrease the proliferation of rhabdomyosarcoma(RD) and vero cell lines. J Cancer SciTher. 2013;5:085-088.
68. Sayed MM, et al. Single fraction compared with multiple fraction re-irradiations in patients with painful bone metastases. J Cancer SciTher. 2013;5:089-093.
69. Bukhvostov AA, et al. An atypical DNA polymerase beta overexpressed in human Aml/Hl-60 malignant cells. J Cancer SciTher. 2013;5:094-099.
70. Kalra J, et al. Kinetics of earlysignaling following ILK inhibition in an in vivo model of breast cancer using digital quantification of stained tissue microarrays. J Cancer SciTher. 2013;5:001-013.
71. Manica GCM, et al. ADAM33 as a new biomarker for invasive lobular breast carcinoma. J Cancer SciTher. 2013;5:014-017.
72. Afzal M, et al. Pharmacological evaluation of gatifloxacin in chemically induced hepatocarcinogenesis: A new tool for hepatocellularcarcinoma treatment. J Cancer SciTher. 2013;5: 018-022.
73. Kim KY, et al. Gene expression profiling from a prostate cancer pc-3 cell line treated with salinomycin predicts cell cycle arrest and endoplasmic reticulum stress. J Cancer SciTher. 2013;5:023-030.
74. Bisen PS. Demystifyingmyths of cancer. J Cancer SciTher. 2013;5:e120.
75. Bhuvaneswari R, et al. Combined use of anti-VEGF and anti-EGFR monoclonal antibodies with photodynamic therapy suppresses tumor growth in an in vivo tumor model. J Cancer SciTher. 2013;5:100-105.
76. Javanbakht J, et al. Evaluation of metastatic cholangiocarcinoma in a spitz dog. J Cancer SciTher. 2013;5:113-114.
77. Nieder C, et al. Landmark studies in radiation oncology: Has the pattern of publication changed? J Cancer SciTher. 2013;5:115-118.
78. Nair HB, et al. 1205Lu Human metastatic melanoma cells, not human! J Cancer SciTher. 2013;5:119-119.
79. Bradford SA and Khan A. Individualizing chemotherapy using the anti-diabetic drug, metformin, as an “adjuvant”: an exploratory study. J Cancer SciTher. 2013;5:120-125.
80. Troyer D. Cell-based targeting of anti-cancer nanotherapy to tumors. J Cancer SciTher. 2013;5:142-143.
81. Mir R, et al. Epigenetic Silencing of DAPK1 gene is associated with faster disease progression in India populations with chronic myeloid leukemia. J Cancer SciTher. 2013;5:144-149.
82. Ratke J, et al. A Novel Role of Adiponectin: Stimulator of human SW480 colon carcinoma cell migration by inducing an autocrine IL-8 and MCP-1 loop. J Cancer SciTher. 2013;5:150-157.
83. Periasamy J, et al. Nimesulide and celecoxib inhibits multiple oncogenic pathways in gastric cancer cells. J Cancer SciTher. 2013;5:126-136.
84. Kamble P, et al. Ultrastructural and antioxidant studies of etoposide treated kidney of rat. J Cancer SciTher. 2013;5:137-141.
85. Ramakrishna SC. Role of leptomycin in p53 induced apoptosis. J Cancer SciTher. 2013;5:158-181.
86. Aljada A, et al. Induction of stress induced premature senescence by sirtuin-7 inhibition: a novel mechanism for multi drug resistance. J Cancer SciTher. 2013;5:182-189.
87. El-Sayed MI, et al. Quality of life in bladder cancer patients treated with radical cystectomy and orthotopic bladder reconstruction versus bladder preservation protocol. J Cancer SciTher. 2013;5:190-193.
88. Ibrahim FF and Ghannam MM. The Diagnostic Potential of Dielectric Properties, Telomerase Activity and Cytokeratin 20 in Urine Cells of Bladder Cancer Patients. J Cancer SciTher. 2012;4:237-242.
89. Elias EG, et al. Targeting melanoma sites in vivo can induce complete tumor ablation and prolong patient survival: an exploratory study. J Cancer SciTher. 2013;5:244-248.
90. vanVuurden DG, et al. Cytotoxicity and radiosensitization of high grade glioma cells by CI-1033, an irreversible Pan-ErbBinhibitor. J Cancer SciTher. 2013;5:249-255.
91. Gangadhara Reddy S, et al. Novel antiproliferative and antioxidant role of BjAnn1, a mustard annexin protein in human glioblastoma cell lines. J Cancer SciTher. 2013;5: 256-263.
92. Tsai YC, et al. A prevalent cancer associated glycan, globoH ceramide, induces immunosuppression by reducing notch1 signaling. J Cancer SciTher. 2013;5:264-270.
93. Manjamalai A, et al. Chemotherapeutic effect of essential oil of wedeliachinensis (osbeck) on inducing apoptosis, suppressing angiogenesis and lung metastasis in C57BL/6 mice model. J Cancer SciTher. 2013;5:271-281.
94. Bouchelouche K, et al. PET/CT and MRI in bladder cancer. J Cancer SciTher. 2013;S14:001.
95. Dileep KV, et al. Approaches in the chemoprevention of breast cancer. J Cancer SciTher. 2013;5:282-288.
96. Zheng D, et al. Myxomaviralanti-inflammatory serpin reduces myeloid-derived suppressor cells and human pancreatic cancer cell growth in mice. J Cancer SciTher. 2013;5:291-299.
97. Pham A, et al. Squamous cell malignancies of the upper urinary tract: A survival study and a systematic Review of the Literature. J Cancer SciTher. 2013;S4:001.
98. Cidón EU. What is the optimal treatment for metastatic colorectal cancer? Controversial Points. J Cancer SciTher. 2011;S4:003.
99. Ino K, et al. Role of the immune tolerance-inducing molecule Indoleamine 2,3-dioxygenase in gynecologic cancers. J Cancer SciTher. 2011;S13:001.
100. Gomez-Cabrero A, et al. NF-κBinhibitor IMD-0354 targets human non-small cell lung cancer stem cells and combined with chemotherapy reduces multidrug resistance. J Cancer SciTher. 2013;5:300-312.